The widely available neutrophil-to-lymphocyte ratio test proved effective in predicting survival in idiopathic pulmonary fibrosis and helped improve use of the Gender-Age-Physiology (GAP) Index for ...

Not intended for US and UK audiencesBI 765423 has been developed to target IL-11, a key driver of fibrosisNew study will investigate potential of ...

Please provide your email address to receive an email when new articles are posted on . Few patients with IPF reported gastrointestinal side effects during buloxibutid treatment. Planned future ...

More than 100 therapies for idiopathic pulmonary fibrosis are being developed across the globe. IPF is a chronic and progressive lung disease that affects the tissue surrounding the air sacs in the ...

Having stacked all its chips on the idiopathic pulmonary fibrosis (IPF) treatment buloxibutid, Vicore Pharma’s bet may be paying off. The Swedish biotech has unveiled final phase 2a data showing the ...

Please provide your email address to receive an email when new articles are posted on . Patients with idiopathic pulmonary fibrosis taking ziritaxestat vs. placebo saw no improvement in lung function ...

In idiopathic pulmonary fibrosis, 12 months of pulmonary rehabilitation increased cerebral oxygenation during exercise, ...

The effect of pollution exposure on IPF severity and progression was not modified by MUC5B promotor polymorphism or telomere length. Long-term exposure to fine particulate matter is associated with a ...

Pooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at week 12, compared to a 2.4% decrease for the ...